{"id":5889,"date":"2024-09-02T12:55:55","date_gmt":"2024-09-02T10:55:55","guid":{"rendered":"https:\/\/thoraxzentrum-ruhrgebiet.de\/zyciorys-dr-hab-n-med-daniela-c-christopha\/"},"modified":"2026-10-23T08:51:13","modified_gmt":"2026-10-23T06:51:13","slug":"zyciorys-dr-hab-n-med-daniela-c-christopha","status":"publish","type":"page","link":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/zyciorys-dr-hab-n-med-daniela-c-christopha\/","title":{"rendered":"\u017byciorys dr. hab. n. med. Daniela C. Christopha"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-2ulvfw-fd448fe86077ab70abc385e5cdd120e4\">\n#top .av-special-heading.av-2ulvfw-fd448fe86077ab70abc385e5cdd120e4{\npadding-bottom:10px;\n}\nbody .av-special-heading.av-2ulvfw-fd448fe86077ab70abc385e5cdd120e4 .av-special-heading-tag .heading-char{\nfont-size:25px;\n}\n.av-special-heading.av-2ulvfw-fd448fe86077ab70abc385e5cdd120e4 .av-subheading{\nfont-size:15px;\n}\n<\/style>\n<div  class='av-special-heading av-2ulvfw-fd448fe86077ab70abc385e5cdd120e4 av-special-heading-h1  avia-builder-el-0  el_before_av_image  avia-builder-el-first '><h1 class='av-special-heading-tag '  itemprop=\"headline\"  >\u017byciorys dr. hab. n. med. Daniela C. Christopha <\/h1><div class=\"special-heading-border\"><div class=\"special-heading-inner-border\"><\/div><\/div><\/div>\n\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-3sm5ik-1fcf19d18429e052d7dd412783c170d4\">\n#top .hr.hr-invisible.av-3sm5ik-1fcf19d18429e052d7dd412783c170d4{\nheight:30px;\n}\n<\/style>\n<div  class='hr av-3sm5ik-1fcf19d18429e052d7dd412783c170d4 hr-invisible  avia-builder-el-2  el_after_av_image  el_before_av_textblock '><span class='hr-inner '><span class=\"hr-inner-style\"><\/span><\/span><\/div>\n<section  class='av_textblock_section av-1ul5cc-f6b4a3eef008426895aebce41a3aabc5 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><h2><strong>Curriculum vitae<\/strong><\/h2>\n<p><strong>1999 \u2013 2002: <\/strong>Studia medyczne na Uniwersytecie Ruhry w Bochum<\/p>\n<p><strong>2002 &#8211; 2005: <\/strong>Studia medyczne na Uniwersytecie Duisburg-Essen<\/p>\n<p><strong>2005 &#8211; 2006: <\/strong>Studia medyczne na Uniwersytecie Ruhry w Bochum<\/p>\n<p><strong> 2006 &#8211; 2015: <\/strong>Pracownik naukowy i lekarz rezydent w klinikach angiologii, endokrynologii, gastroenterologii i hepatologii, kardiologii i nefrologii w ramach Centrum Medycyny Wewn\u0119trznej oraz w Klinice Chor\u00f3b Wewn\u0119trznych (Badania nad Nowotworami) i w klinikach hematologii i transplantacji szpiku kostnego w ramach Centrum Onkologii Zachowawczej<\/p>\n<p><strong>2016 &#8211; 2017: <\/strong>Pracownik naukowy (starszy asystent) i kierownik grupy roboczej (Labor Bada\u0144 Onkologii Klatki Piersiowej) Kliniki Chor\u00f3b Wewn\u0119trznych (Badania nad Nowotworami), Szpital Uniwersytecki w Essen<\/p>\n<p><strong>2017 &#8211; 2021: <\/strong>Starszy asystent w Klinice Onkologii Internistycznej i Paliatywnej, Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte<\/p>\n<p><strong>2021 <\/strong><strong>&#8211; 2024: <\/strong>Kierownik starszych asystent\u00f3w w Klinice Onkologii Internistycznej i Paliatywnej, Evangelische Huyssensstiftung, Evangelische Kliniken Essen-Mitte<\/p>\n<p><strong>2018 &#8211; 2022: <\/strong>Zatrudniony lekarz specjalista w Medycznym Centrum Opieki Hematologii i Onkologii Essen gGmbH<\/p>\n<p><strong>2024 &#8211; obecnie: <\/strong>Kierownik Sekcji Onkologii Klatki Piersiowej, Klinika Pneumonologii i Infektologii, Evang. Krankenhaus Herne-Eickel<\/p>\n<h2>Uznanie, stypendia i wyr\u00f3\u017cnienia<\/h2>\n<p><strong>2010 \u2013 2012:<\/strong> \u201e<em>International Association for the Study of Lung Cancer (IASLC) Fellowship Award<\/em>\u201d<\/p>\n<p><strong>2011:<\/strong> \u201e<em>American Society of Clinical Oncology (ASCO) Foundation Merit Award<\/em>\u201d<\/p>\n<p><strong><b>2015: <\/b><\/strong>Uznanie jako specjalista chor\u00f3b wewn\u0119trznych ze specjalizacj\u0105 hematologia \/ onkologia<\/p>\n<h2>Cz\u0142onkostwo w naukowych towarzystwach specjalistycznych<\/h2>\n<p>ASCO (<em>American Society of Clinical Oncology<\/em>)<\/p>\n<p>DGHO (Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie)<\/p>\n<p>ESMO (<em>European Society of Medical Oncology<\/em>)<\/p>\n<p>IASLC (<em>International Association for the Study of Lung Cancer<\/em>)<\/p>\n<h2>Dzia\u0142alno\u015b\u0107 badawcza w badaniach klinicznych (g\u0142\u00f3wny badacz)<\/h2>\n<p><strong>BI1199.93<\/strong>:<em> \u201eDouble blind, randomized, multicenter, phase II study of nintedanib in combination with pemetrexed \/ cisplatin followed by continuing nintedanib monotherapy versus placebo in combnation with pemetrexed \/ cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma\u201d<\/em><\/p>\n<p><strong>MORAb-009-201<\/strong>: <em>\u201eA Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma\u201d<\/em><\/p>\n<p><strong><em>BAY 94-9343 \/ 15743: <\/em><\/strong><em>\u201eA randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum\/pemetrexed-based chemotherapy\u201d<\/em><\/p>\n<p><strong><em>CheckMate743:<\/em><\/strong><em> Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients<\/em><\/p>\n<p><strong><em>Roche Immotion WO29637<\/em><\/strong><em>: \u201eA phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma\u201c<\/em><\/p>\n<p><strong><em>CheckMate 592:<\/em><\/strong><em> \u201cAn Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)\u201d <\/em> <\/p>\n<p><strong><em>AIO-YMO\/TRK-0416: \u201c<\/em><\/strong><em>Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC\u201d<\/em><\/p>\n<p><strong><em>KEYLYNK-006:<\/em><\/strong><em> \u201e<\/em><em>A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed\/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer\u201d<\/em><\/p>\n<p><strong><em>KEYLYNK-008:<\/em><\/strong><em> \u201e<\/em><em>A Phase 3 Study of Pembrolizumab in Combination with Carboplatin\/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)\u201d<\/em><\/p>\n<p><strong><em>NICITA:<\/em><\/strong><em> \u201cNivolumab with chemotherapy in pleural mesothelioma after surgery\u201d<\/em><\/p>\n<p><strong><em>CONTACT-01 (GO41892):<\/em><\/strong><em> A Phase III, multicenter, randomized, open-label, controlled Study to evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab given in Combination with Cabozantinib versus Docetaxel Monotherapy in Patients with Metastatic Non-Small Cell Lung Cancer previously treated with an Anti-PD-L1\/PD-1 Antibody and Platinum containing Chemotherapy.<\/em><\/p>\n<p><strong><em>MK3475-789: <\/em><\/strong><em>A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants.<\/em><\/p>\n<p><strong><em>CheckMate 73L (CA209-73L):<\/em><\/strong><em> A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer<\/em><\/p>\n<p><strong><em>DOLPHIN:<\/em><\/strong><em> A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin \/ Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin \/ Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer.<\/em><\/p>\n<p><strong><em>SAPPHIRE\/MIRATI 516-005:<\/em><\/strong><em> \u201cA Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy\u201d<\/em><\/p>\n<p><strong><em>MIRATI 849-012:<\/em><\/strong><em> \u201cA Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation\u201d<\/em><\/p>\n<p><strong><em>MyRisk\/IBA1160:<\/em><\/strong><em> \u201cEfficacy and safety evaluation of oral Akynzeo\u00ae in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study\u201d<\/em><\/p>\n<p><strong><em>CA224104\/RELATIVITY-104:<\/em><\/strong><em> \u201cA Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)\u201d<\/em><\/p>\n<p><strong><em>IMforte\/GO43104:<\/em><\/strong><em> \u201cA Phase III, randomized, open-label, Multicenter Study of Lurbinectidin in Combination with Atezolizumab compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Ffollowing First-Line<\/em><\/p>\n<p><em>Induction Therapy With Carboplatin, Etoposide and Atezolizumab\u201d<\/em><\/p>\n<p><strong><em>ANTELOPE:<\/em><\/strong><em> \u201cAtezolizumab\/Carboplatin\/Nab-Paclitaxel vs. Pembrolizumab\/Platinum\/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma<\/em><\/p>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":252,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5889","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/pages\/5889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/comments?post=5889"}],"version-history":[{"count":3,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/pages\/5889\/revisions"}],"predecessor-version":[{"id":5892,"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/pages\/5889\/revisions\/5892"}],"wp:attachment":[{"href":"https:\/\/thoraxzentrum-ruhrgebiet.de\/pl\/wp-json\/wp\/v2\/media?parent=5889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}